Jana Fassunke

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Sandra Ortiz‐Cuaran, Matthias Scheffler, Dennis Plenker et al. · Clinical Cancer Research · 2016 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler, Michaela A. Ihle, Rebecca Hein et al. · Journal of Thoracic Oncology · 2018 · 259 citations · Full text

Medicine, Genetics, Oncology +17

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations

Michaela A. Ihle, Jana Fassunke, Katharina König et al. · BMC Cancer · 2014 · 251 citations · Full text

Medicine, Genetics, Oncology +17

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Anna Kron, Christina Alidousty, Matthias Scheffler et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

Hans‐Ulrich Schildhaus, Anne M. Schultheis, Josef Rüschoff et al. · Clinical Cancer Research · 2014 · 189 citations

Medicine, Genetics, Oncology +17